Related Experiment Video
Updated: Apr 6, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Clinical considerations for biosimilar antibodies.
1Professor of Oncological Biotherapy, Department of Oncology-Pathology, Karolinska Institute, SE-171 76 Stockholm, Sweden.
Summary
Biosimilar monoclonal antibodies (mAbs) are complex biologic copies. This review critically examines their structural nuances, clinical impact, and pharmacoeconomic implications, emphasizing the need for further discussion.
Area of Science:
- Biotechnology
- Pharmacology
- Immunology
Background:
- Biosimilar agents are highly similar versions of approved biologic therapies.
- The European Medicines Agency has authorized numerous biosimilars since 2006, including two biosimilar monoclonal antibodies (mAbs).
- Biosimilar mAbs possess unique characteristics due to their large size, intricate protein structure, and post-translational modifications.
Purpose of the Study:
- To critically evaluate the structural complexity of biosimilar mAbs.
- To assess the feasibility of indication extrapolation for biosimilar mAbs.
- To discuss the implications of biosimilar mAbs on immunogenicity, pharmacovigilance, and pharmacoeconomics.
Main Methods:
- Literature review and critical analysis of existing data on biosimilar monoclonal antibodies.
- Examination of regulatory guidelines and scientific publications concerning biosimilar development and approval.
- Discussion of key scientific and clinical considerations for biosimilar mAbs.
Main Results:
- Biosimilar mAbs present unique challenges owing to their complex molecular structure and manufacturing processes.
- Indication extrapolation for biosimilar mAbs requires careful scientific justification.
- Product variability can influence immunogenicity, necessitating robust pharmacovigilance.
Conclusions:
- Further research and discussion are essential to fully comprehend the clinical and pharmacoeconomic impact of biosimilar mAbs.
- Comprehensive pharmacovigilance strategies are crucial for ensuring the safety and efficacy of biosimilar mAbs.
- The unique attributes of biosimilar mAbs warrant specific considerations in regulatory and clinical practice.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
353
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
353
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
00:42Cross-reactivity
33.9K
Overview
33.9K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
216
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
216
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
246
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
246